141 related articles for article (PubMed ID: 36581914)
1. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design.
Doppenberg D; Besselink MG; van Eijck CHJ; Intven MPW; Koerkamp BG; Kazemier G; van Laarhoven HWM; Meijerink M; Molenaar IQ; Nuyttens JJME; van Os R; van Santvoort HC; van Tienhoven G; Verkooijen HM; Versteijne E; Wilmink JW; Lagerwaard FJ; Bruynzeel AME;
BMC Cancer; 2022 Dec; 22(1):1363. PubMed ID: 36581914
[TBL] [Abstract][Full Text] [Related]
2. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE).
van Goor IWJM; Daamen LA; Besselink MG; Bruynzeel AME; Busch OR; Cirkel GA; Groot Koerkamp B; Haj Mohammed N; Heerkens HD; van Laarhoven HWM; Meijer GJ; Nuyttens J; van Santvoort HC; van Tienhoven G; Verkooijen HM; Wilmink JW; Molenaar IQ; Intven MPW;
Trials; 2022 Oct; 23(1):913. PubMed ID: 36307892
[TBL] [Abstract][Full Text] [Related]
3. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).
Pavic M; Niyazi M; Wilke L; Corradini S; Vornhülz M; Mansmann U; Al Tawil A; Fritsch R; Hörner-Rieber J; Debus J; Guckenberger M; Belka C; Mayerle J; Beyer G
Radiat Oncol; 2022 Jan; 17(1):18. PubMed ID: 35078490
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Body radiotherapy and pedicLE screw fixatioN During one hospital visit for patients with symptomatic unstable spinal metastases: a randomized trial (BLEND RCT) using the Trials within Cohorts (TwiCs) design.
Huele EH; van der Velden JM; Kasperts N; Eppinga WSC; Grutters JPC; Suelmann BBM; Weening AA; Delawi D; Teunissen SCCM; Verkooijen HM; Verlaan JJ; Gal R
Trials; 2023 May; 24(1):307. PubMed ID: 37143158
[TBL] [Abstract][Full Text] [Related]
5. Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design.
Doppenberg D; Besselink MG; van Eijck CHJ; Intven MPW; Groot Koerkamp B; Kazemier G; van Laarhoven HWM; Meijerink M; Molenaar IQ; Nuyttens JJME; van Os R; van Santvoort HC; van Tienhoven G; Verkooijen HM; Versteijne E; Wilmink JW; Lagerwaard FJ; Bruynzeel AME;
BMC Cancer; 2023 Jan; 23(1):70. PubMed ID: 36670370
[No Abstract] [Full Text] [Related]
6. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
7. SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.
Fredman E; Icht O; Moore A; Bragilovski D; Kindler J; Golan S; Limon D
BMC Cancer; 2024 Apr; 24(1):431. PubMed ID: 38589860
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
9. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
10. Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC).
Kim YB; Byun HK; Wee CW; Kim H; Kim S; Yang G; Kim J; Park SJ; Lee JY
BMC Cancer; 2023 Oct; 23(1):1014. PubMed ID: 37864152
[TBL] [Abstract][Full Text] [Related]
11. Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Correa RJM; Morton G; Chung HT; Tseng CL; Cheung P; Chu W; Liu SK; McGuffin M; Shahid A; Davidson M; Ravi A; Helou J; Alayed Y; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2022 Apr; 169():51-56. PubMed ID: 35151715
[TBL] [Abstract][Full Text] [Related]
12. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
15. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.
Olson R; Abraham H; Leclerc C; Benny A; Baker S; Matthews Q; Chng N; Bergman A; Mou B; Dunne EM; Schellenberg D; Jiang W; Chan E; Atrchian S; Lefresne S; Carolan H; Valev B; Tyldesley S; Bang A; Berrang T; Clark H; Hsu F; Louie AV; Warner A; Palma DA; Howell D; Barry A; Dawson L; Grendarova P; Walker D; Sinha R; Tsai J; Bahig H; Thibault I; Koul R; Senthi S; Phillips I; Grose D; Kelly P; Armstrong J; McDermott R; Johnstone C; Vasan S; Aherne N; Harrow S; Liu M
BMC Cancer; 2024 Feb; 24(1):171. PubMed ID: 38310262
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design.
Hoffe SE; Aguilera TA; Parikh PJ; Ghaly MM; Herman JM; Caster JM; Kim DW; Costello J; Malafa MP; Moser EC; Kennedy EP; Terry K; Kurman M
Future Oncol; 2024 Mar; 20(8):437-446. PubMed ID: 38264869
[TBL] [Abstract][Full Text] [Related]
17. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma.
Quan K; Sutera P; Xu K; Bernard ME; Burton SA; Wegner RE; Zeh H; Bahary N; Stoller R; Heron DE
Pract Radiat Oncol; 2018; 8(2):95-106. PubMed ID: 29291966
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer.
Mutsaers A; Greenspoon J; Walker-Dilks C; Swaminath A
Radiat Oncol; 2017 Jun; 12(1):110. PubMed ID: 28662680
[TBL] [Abstract][Full Text] [Related]
19. A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.
Biau J; Thivat E; Millardet C; Saroul N; Pham-Dang N; Molnar I; Pereira B; Durando X; Bourhis J; Lapeyre M
BMC Cancer; 2020 Aug; 20(1):730. PubMed ID: 32758188
[TBL] [Abstract][Full Text] [Related]
20. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
